ArticleIJU case reports2026
Complete Response to Concurrent Triplet Therapy in Low-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Case Report.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Triplet therapy with androgen deprivation therapy (ADT), an androgen receptor pathway inhibitor, and docetaxel improves survival in metastatic hormone-sensitive prostate cancer (mHSPC), but its role in low-volume disease remains unclear. Case Presentation: A 68-year-old man presented with dysuria and a PSA increase to 34.49 ng/mL. Imaging revealed a prostate tumor extending into the bladder, right obturator lymph node metastasis, and a bone lesion. Biopsy showed Gleason score 5 + 5 prostate adenocarcinoma (cT4N1M1b low-volume mHSPC). Concurrent triplet therapy with ADT, darolutamide, and docetaxel was initiated. PSA decreased to 0.1 ng/mL within 2 months, and imaging at 4.5 months demonstrated a radiological complete response. At the latest follow-up (7 months), the PSA remained below 0.03 ng/mL without progression to CRPC. Conclusion: Concurrent triplet therapy may achieve complete response in selected patients with aggressive low-volume mHSPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.